Pantziarka Pan, Bouche Gauthier, Meheus Lydie, Sukhatme Vidula, Sukhatme Vikas P
Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium ; The George Pantziarka TP53 Trust, London KT1 2JP, UK.
Anticancer Fund, Brussels, 1853 Strombeek-Bever, Belgium.
Ecancermedicalscience. 2014 Nov 26;8:485. doi: 10.3332/ecancer.2014.485. eCollection 2014.
Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.
西咪替丁是首个广泛应用于临床的H2受体拮抗剂，具有抗癌特性，已在针对多种不同癌症类型的广泛临床前和临床研究中得到阐明。这些数据根据多种不同的作用机制进行了总结和讨论。基于所提供的证据，有人提出西咪替丁可与一系列其他药物协同作用，包括现有的化疗药物，因此有必要进一步探索西咪替丁作为抗癌治疗药物的潜力。此外，有令人信服的证据表明，围手术期使用西咪替丁可能会使某些癌症患者受益。本文的补充材料中讨论了与其他药物的一些可能组合。
